Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated January 6, 2020, reports the successful completion of a tender offer to acquire all outstanding shares of The Medicines Company (NASDAQ: MDCO). The transaction was executed by Novartis's indirect wholly-owned subsidiary, Medusa Merger Corporation.
Key Financial Metrics and Transaction Details
- Acquisition Price: USD 85.00 per share in cash, net to the seller.
- Shares Tendered: 60,669,325 shares (approximately 75.0% of outstanding shares) were validly tendered and not withdrawn.
- Notices of Guaranteed Delivery: 13,655,837 additional shares (approximately 16.9% of outstanding shares).
- Total Coverage: The tender offer and guaranteed delivery notices covered approximately 91.9% of The Medicines Company's outstanding common stock.
- Payment Status: Novartis accepted all validly tendered shares for payment on January 4, 2020.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for Novartis or The Medicines Company for this period.
Material Changes and Transaction Mechanics
Following the tender offer, Novartis will complete the acquisition through a merger of Medusa Merger Corporation with and into The Medicines Company under Section 251(h) of the Delaware General Corporation Law. This process does not require a vote of The Medicines Company's stockholders. Upon the effective time of the merger:
- The Medicines Company will become an indirect wholly-owned subsidiary of Novartis.
- Remaining outstanding shares (excluding those owned by Novartis or its subsidiaries) will be converted into the right to receive USD 85.00 per share in cash.
- The Medicines Company common stock ceased trading on the NASDAQ Global Select Market as of January 6, 2020.
Outlook, Risks, and Management Commentary
Novartis highlights its established presence in cardiovascular, renal, and metabolic diseases, citing its product Entresto and a growing pipeline of potentially first-in-class molecules. The acquisition is intended to expand this portfolio.
Risks and Contingencies: The filing includes extensive forward-looking statements and disclaimers regarding significant risks, including:
- Regulatory actions or delays affecting the acquisition or the development of inclisiran (The Medicines Company's key asset).
- Failure to meet closing conditions or realize expected strategic benefits and synergies.
- Challenges in integrating The Medicines Company into the Novartis Group.
- Uncertainties in clinical trial results, intellectual property protection, and manufacturing.
- Global healthcare cost containment and pricing pressures.
Key Facts for Investor Verification
- Verify the final closing date of the merger and the exact total consideration paid to shareholders.
- Confirm the regulatory approval status of inclisiran in key markets (US, EU) post-acquisition.
- Monitor Novartis's subsequent financial reports for the impact of this acquisition on R&D expenses and goodwill.
- Assess the integration progress of The Medicines Company's commercial and R&D teams into Novartis's Cardiovascular-Renal-Metabolism division.